米斯特拉斯集团

最新新闻

• Henlius Biopharma (02696.HK): The National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for the marketing authorization of HLX14, a denosumab biosimilar, in the 120 mg (1.7 ml)/vial specification.
  Gelonghui Finance · 2026/9/11
• 公司公告
  UNITAS HOLD: Form of proxy for use at the annual general meeting to be held at Flat C, 16/F., MG Tower, 133 Hoi Bun Road, Kwun Tong, Kowloon, Hong Kong on Wednesday, 30 September 2026 at 11:00 a.m. or any adjournment thereof (the "Annual General Meeting")
  HKEX · 2026/9/4
• 评级变动
  Roth MKM Maintains Mistras Group(MG.US) With Buy Rating, Maintains Target Price $22
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Zhongsheng Pharmaceutical (002317): Results from the Phase II RAY1225 study were presented at ADA, with the 18 mg dose group demonstrating superior weight‑loss efficacy.
  Zheshang Securities · 2026/6/10
• Novo Nordisk Announces New Retrospective Real-world Evidence For Type 2 Diabetes Showing Semaglutide Injection 2 Mg Was Associated With A Statistically Significant 6% Lower Risk Of Major Adverse Cardiovascular Events, Than Those Who Switched To...
  Benzinga · 2026/9/29
• 公司公告
  Eisai: The subcutaneous formulation of the early-stage Alzheimer's disease treatment "Rekembi," the "Rekembi Subcutaneous Injection 250 mg Pen," has received approval in Japan.
  JPX · 2026/9/16
• 公司公告
  Nippon Kayaku: A contract has been concluded regarding the succession of manufacturing and marketing approval for "Zoladex 3.6 mg Depot/LA 10.8 mg Depot."
  JPX · 2026/5/25
• 评级变动
  EF Hutton: The MISTRAS Group (MG.US) rating was downgraded from buy to hold, and the target price was adjusted from $12.00 to $11.00.
  Zhitong Finance · 2024/5/3
• Shijiazhuang No.4 Pharmaceutical Group (02005.HK): Obtained drug production registration approval for Vitamin K1 Injection (1ml: 10mg)
  Gelonghui Finance · 2026/8/20
• 公司公告
  Zhongguancun: Announcement Regarding the Receipt by Its Subsidiary, Beijing Huasuo Duotinole Tablets (1 mg and 2 mg), of the \"Notice of Acceptance\" from the National Medical Products Administration.
  SZSI · 2026/8/6
• Fuji Pharmaceutical Co., Ltd. — Eltrombopag Tablets 12.5 mg 'F' and Eltrombopag Tablets 25 mg 'F' have been listed in the National Health Insurance Drug Price Standards and are newly launched.
  Fisco Japan · 2026/6/15
• Eli Lilly Announces Detailed Results From TRIUMPH-2; TRIUMPH-2 Participants With Obesity And Type 2 Diabetes Taking Retatrutide 12 Mg Lost An Average Of 49.6 Lbs Over 80 Weeks; Retatrutide 12 Mg Leads To 60.8 Lb Weight Loss In BMI ≥35 Group; To Submit...
  Benzinga · 2026/9/30
• 评级变动
  Roth MKM Initiates Mistras Group(MG.US) With Buy Rating, Announces Target Price $22
  \u5e02\u573a\u8d44\u8baf · 2026/4/30
• 公司公告
  Fuji Pharma: Marketing Approval for new specification of Golimumab Biosimilar― GOLIMUMAB BS 50mg autoinjector for S.C. injection「F」 ―
  JPX · 2026/9/16
• 评级变动
  TR | OpenAI - 4o Maintains Mistras Group(MG.US) With Hold Rating, Maintains Target Price $9.5
  \u5e02\u573a\u8d44\u8baf · 2025/8/11
• 评级变动
  Texas Capital Securities Initiates Mistras Group(MG.US) With Buy Rating, Announces Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2025/11/21

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。